Table 1:
Demographic and neuropathological characteristics of ROS brain donors included in this study.
| LA-NCI | HA-NCI | MCI | AD | p value (ANOVA) | |
|---|---|---|---|---|---|
| n = | 43 | 16 | 19 | 20 | |
| Percent female | 53% | 48% | 58% | 55% | 0.82 |
| Age (years) | 78.2 ± 7.5 | 84.5 ± 7.9 | 83.9 ± 7.6 | 82.7 ± 8.2 | 0.01 |
| Post-mortem interval (hr) | 10.4 ± 8.3 | 8.5 ± 10.0 | 8.9 ± 5.6 | 5.7 ± 3.7 | 0.16 |
| Years of education | 17.8 ± 3.9 | 18.3 ± 2.8 | 18.2 ± 4.0 | 18.1 ± 3.9 | 0.73 |
| Cerebral amyloid-β percent area | 0.4 ± 0.6 | 2.2 ± 2.1 | 2.8 ± 2.4 | 4.3 ± 3.5 | <0.0001 |
| NFT density/mm2 | 1.6 ± 1.8 | 3.6 ± 4.8 | 5.1 ± 6.7 | 13.7 ± 19.1 | <0.0001 |
| CERAD | 3.3 ± 1.1 | 2.3 ± 0.6 | 2.8 ± 1.1 | 1.9 ± 0.8 | <0.0001 |
| REAGAN | 2.9 ± 0.5 | 2.3 ± 0.5 | 2.4 ± 0.7 | 2.2 ± 0.8 | <0.0001 |
| BRAAK | 2.1 ± 1.2 | 3.7 ± 1.1 | 3.5 ± 0.8 | 3.6 ± 1.1 | <0.0001 |
| APOE ε4 allele frequency | 0.12 | 0.20 | 0.18 | 0.17 | 0.31 |
| Global Cognitive Score (z score) | 0.18 ± 0.33 | −0.04 ± 0.28 | −0.22 ± 0.30 | −2.44 ± 1.11 | <0.0001 |
Data is presented as mean ± standard deviation. LA-NCI: low amyloid-no cognitive impairment, HA-NCI: high amyloid-no cognitive impairment, MCI: mild cognitive impairment, AD: Alzheimer’s disease, NFT: neurofibrillary tangles. The p value column gives the result of a one-way ANOVA comparing the means of all four pathological group.